Pre-exposure Prophylaxis with Tixagevimab-cilgavimab did not Reduce Severity of COVID-19 in Lung Transplant Recipients with Breakthrough Infection

Lung transplant recipients (LTRs) have an increased risk of COVID-19–related morbidity and mortality. Tixagevimab-cilgavimab (tix-cil) is a long-acting monoclonal antibody combination granted Emergency Use Authorization approval by the US Food and Drug Administration for COVID-19 pre-exposure prophy...

Descripción completa

Detalles Bibliográficos
Autores principales: Sindu, Devika, Razia, Deepika, Grief, Katherine, Cherrier, Lauren, Omar, Ashraf, Walia, Rajat, Tokman, Sofya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Lung Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184979/
https://www.ncbi.nlm.nih.gov/pubmed/37197016
http://dx.doi.org/10.1097/TXD.0000000000001485

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184979/
https://www.ncbi.nlm.nih.gov/pubmed/37197016
http://dx.doi.org/10.1097/TXD.0000000000001485

Ejemplares similares